12.3.2012 | Newly on Gate2Biotech
Several biological drugs will go off patent over the next years. In fact, biologics with estimated total sales value of USD 63 bn (approx. 40% of forecast market) are expected to lose patent protection by 2015 globally, rising to more than USD 100 bn by 2020. The EU has been leading the world in the introduction of biosimilars since it approved...
5.3.2012 | Newly on Gate2Biotech
Present situation of the market of personalized medicine has reached just a tip of the iceberg. There are obstacles to overcome all around the world, such as specific environments, different investment systems, popular one-size-fits-all treatment model, and above all – mutual assistance. As indicated by Frost&Sullivan, a renowned business and...
16.2.2012 | Newly on Gate2Biotech
Biotech scientists are full of ideas. Some ideas are fanciful and never tested. Some ideas are tested and fail the tests. Others are tested and found to be worthy of implementation and commercialization. How are ideas created? How are ideas tested and implemented? How do ideas contribute to scientific knowledge? How are ideas marketed and sold?...
13.2.2012 | Newly on Gate2Biotech
The timber industry currently wastes huge amounts of precious wood by-products like chips, shavings and sawdust that could otherwise be put to use. European researchers, with the support of EU funding, are finding new ways to ensure every little bit counts.
8.2.2012 | Newly on Gate2Biotech
European Commission workshop outlines the Bioeconomy’s impact in our lives. Stirring lessons in science and innovation were delivered in Brussels on Tuesday February 7 at a European Commission workshop devoted to the Bioeconomy.
18.1.2012 | Newly on Gate2Biotech
HAYS Czech Republic, leading global experts in qualified in professional and skilled recruitment, joints to BioForum 2012 (www.cebioforum.com) event, held in Brno, Czech Republic May 23-24th, 2012 and organizes a career day oriented on pharmaceutical and biotech market.
11.1.2012 | Newly on Gate2Biotech
Central Europe (CE) is becoming a new emerging market for CROs (Clinical Research Organizations). Fast growing outsourcing of clinical studies in CE region creates new opportunities for pharma and biotech companies facing with cost and time consuming process of drug delivery to the market.
20.12.2011 | Newly on Gate2Biotech
Central Europe (CE) is an emerging biotech market, a small star among European regions. There are more or less 200 innovative biotech companies, which mostly were established in last 10 years. During the 11th edition of BioForum, Central European Forum of Biotechnology and Innovative BioEconomy, held in Brno, Czech Republic, May 23-24th 2012...
5.12.2011 | Newly on Gate2Biotech
Anti-counterfeiting, packaging safely via redesign, 2D barcoding integrity and artwork management updates are just a few among the major themes of Fleming Europe’s 2nd Annual Pharma Packaging & Labeling Compliance Conference which is once again bringing you three days of ground-breaking debate and pioneering case studies from top industry,...
16.11.2011 | Newly on Gate2Biotech
How to make your proposal succeed in Framework Programme 7? The crucial parameters are scientific quality of proposal, implementation plan and potential impact of the carried proposal. Seminar is focused on these problems.
Gate2Biotech - Biotechnology Portal - All Czech Biotechnology information in one place.
ISSN 1802-2685
This website is maintained by: CREOS CZ
© 2006 - 2024 South Bohemian Agency for Support to Innovative Enterprising (JAIP)
Interesting biotechnology content:
Biotechnology portal - at Wikipedia. Useful information for you.
Biotechnology education - National biotechnology education centre
Coaxing purple bacteria into becoming bioplastic factories
Novel nanoparticles can trap and neutralize large amounts of SARS-CoV-2